• Corpus ID: 40673698

Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients.

  title={Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients.},
  author={F. H. Noormohamed and Mike S Youle and Bin Tang and Sarah Martin-Munley and Brian George Gazzard and A. F. Lant},
  journal={Antiviral therapy},
  volume={1 3},
The time course and magnitude of foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium were investigated in 13 male HIV-positive patients who had no active cytomegalovirus-associated disease. The patients had a mean age of 36 years (range 25-49 years) and a mean CD4 cell count of 550 cells/mm3 (range 130-1280 cells/mm3). Peak (mean +/- SD) plasma concentrations of foscarnet (0.89+/-0.10 mmol/l) were seen at the end of the period of drug infusion (90 mg/kg… 
Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
The study shows that foscarnet is not transported via the probenecid-sensitive organic acid secretory pathway in the proximal tubule; the renal elimination of foscaret is via glomerular filtration.
Pharmacokinetics and Absolute Bioavailability of Oral Foscarnet in Human Immunodeficiency Virus-Seropositive Patients
The pharmacokinetics, absolute bioavailability, accumulation, and tolerability over 8 days of an oral formulation of foscarnet are investigated, suggesting that the formulation studied would require significant improvement with respect to tolerability and bioavailability to gain clinical acceptance.
A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection
Overall, increasing doses of MgSO4 reduced or eliminated foscarnet-induced acute ionized hypomagnesemia, suggesting that intravenous supplementation with up to 3 g of M gSO4 was safe in this chronically ill population of patients with AIDS and cytomegalovirus disease.
Minimising the Dosage-Limiting Toxicities of Foscarnet Induction Therapy
New ways to manage the dose-limiting adverse reactions caused by foscarnet are suggested so that this agent may be used with confidence as first-line therapy in patients with cytomegalovirus (CMV) disease.
Hypomagnesemia in the Cancer Patient
Checking serum magnesium at the beginning of treatment and as part of routine monitoring throughout cancer treatment is recommended, and further characterization of hypomagnesemia on the clinical impact on cancer outcomes is highlighted.
Practical Interest of Circulating Total and Ionized Magnesium Concentration Evaluation in Experimental and Clinical Magnesium Disorders
Magnesium (Mg) is essentially an intracellular ion, which makes it difficult to evaluate Mg status. Both circulating total (MgT) and ionized Mg2+ (MgI) are used in clinical practice but their
Magnesium in man: implications for health and disease.
An extensive and comprehensive overview of Mg(2+) research over the last few decades is provided, focusing on the regulation of M g(2+) homeostasis in the intestine, kidney, and bone and disturbances which may result in hypomagnesemia.
Drug-induced alterations in Mg2+ homoeostasis.
A better understanding of the molecular mechanisms underlying the adverse effects of these medications on Mg2+ balance will indicate ways of prevention and treatment of these adverse effects and could potentially provide more insight into Mm2+ homoeostasis.
Magnesium metabolism and its disorders.
Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis and the use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed.
Infección sistémica por citomegalovirus: influencia del tratamiento con foscarnet en los niveles plasmáticos de calcio y magnesio
The case of a paediatric cardiac transplant patient who developed electrolyte disturbances during foscarnet treatment for cytomegalovirus infection, which resolved after 6 weeks of treatment.